Webinars

Prof. Dr. Jörn M. Schattenberg

• Dr. Jörn M. Schattenberg is a Professor of Medicine and Director of the Department of Medicine II at Saarland University Medical Center in Homburg and the University of the Saarland in Germany.
• Dr. Schattenberg completed his post-doctoral training at Albert-Einstein College of Medicine in New York, focusing on signaling pathways involved in acute and chronic liver injury, particularly in metabolic dysfunction associated steatotic liver disease (MASLD).
• He is board-certified in Internal Medicine, Gastroenterology & Hepatology, and Infectious Disease.
• His research specializes in translational sciences and clinical trials in Hepatology, with a focus on new technologies and approaches for the prevention, screening, and treatment of metabolic liver disease.
• Dr. Schattenberg is involved in multinational, EU-funded research consortia exploring biomarkers and novel treatment methods for liver diseases.
• He is a member of the Policy, Public Health, and Advocacy Committee of the European Association for the Study of the Liver (EASL).
• He serves on the Editorial Boards of “Hepatology” and “Alimentary Pharmacology & Therapeutics” and is an Associate Editor for “JHEP Reports.”

Reserve a seat

Dr. Diana J. Leeming

• Dr. Diana Julie Leeming is the Senior Director of Fibrosis, Hepatic, and Pulmonary Research at Nordic Bioscience.
• She joined Nordic Bioscience in 2004 and assumed the role of Director of Fibrosis in 2010, later being promoted to Senior Director in 2024.
• Dr. Leeming focuses on developing serologically assessed markers to evaluate extracellular matrix remodeling in patients with pulmonary or hepatic fibrosis, aiding in diagnosis and pharmacodynamic evaluation.
• She is a principal inventor of the PRO-C3 assay, a fibrogenesis marker utilized in multiple clinical trial studies.
• Dr. Leeming has authored over 280 peer-reviewed publications, demonstrating her extensive contributions to the field.
• Her H-index is 61, her I10-index is 174, and her research has garnered over 11,825 citations as of March 2024.

Agenda*

11:00 – 11:10 | Opening of the session

11:10 – 11:30 | Metabolic activation and de-activation of fibroblasts in MAFLD by weight loss. The weight-dependent angle – Professor Jörn M. Shattenberg

11:30 – 11:50 | Metabolic activation of ECM production of fibroblast and the relation to outcomes in heart, liver and kidney diseases – Professor Morten Karsdal

11:50 – 12:10 | Pharmacological modulation of fibroblast activation and the benefit for patients –Dr. Diana J. Leeming

12:10 – 12:30 | General discussion and questions

*All times EDT. Agenda is subject to change as per speaker availability.

Register now

Dr. Morten Karsdal

• Dr. Morten Karsdal joined Nordic Bioscience in 2001 and became CEO in June 2010, leading the company to significant advancements in biomarker development and disease biology.
• Dr. Karsdal is an honorary professor of inflammation research at the University of Southern Denmark, where he continues to supervise PhD students, fostering the next generation of researchers.
• Dr. Karsdal chairs the Extracellular Matrix Pharmacology Congress, an important forum for advancing drug development by focusing on the extracellular matrix (ECM) as a key factor in most chronic diseases. He is renowned for his deep expertise in fibrosis, rheumatology (including rheumatoid arthritis and osteoarthritis), diabetes, and other chronic conditions, particularly in relation to ECM and biomarker research.
• Dr. Karsdal has led the development of FDA-approved and supported molecular diagnostics, as well as more than 100 commercialized biomarker assays, including ELISA assays and high precision automated platforms.
• He has extensive experience in clinical trial design and the clinical application of biochemical markers, often serving as a consultant to major pharmaceutical companies for the use of serological biomarkers in clinical trials.
• In 2016, he and his research team authored the first edition of “Biochemistry of Collagens, Laminins and Elastin,” published by Elsevier Science. The book, now in its 3rd edition as of 2023, is a key resource on collagens and structural proteins, with a focus on their applications in chronic diseases.